



RE104 Safety and Efficacy Study in Adjustment Disorder in Patients with Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS) and Parkinson's Disease (PD)

According to [Reunion Neuroscience](#), Adjustment Disorder (AjD) is a mental health condition defined as a disproportionate reaction to a stressful life event or change, which impacts the ability to function and is characterized by depression, anxiety and/or other behavioral and mood disturbances. Serious medical illnesses like Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) are known to be a key precipitant of AjD; it is estimated that approximately 500,000 people in the United States are diagnosed with AjD each year following a medical or health-related stressor. Current treatments for AjD are not consistently effective, and there are no therapies presently approved by the U.S. Food and Drug Administration (FDA) for its treatment.



RE104, is a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT. Reunion designed RE104 to deliver a short duration psychedelic experience compared to longer duration psychedelics like psilocybin. The REKINDLE Phase 2 clinical trial is a randomized, double-blind, parallel-group, dose-controlled clinical trial evaluating the safety and efficacy of RE104 for the treatment of AjD in adult patients with ALS, MS and Parkinson's disease.

(Hawaii REKINDLE Team – Kyung Moo Kim, MD, Psychiatry, Kore Liow, MD, Neurology, Natalia Gonzalez, MD, Neurology (PI) Janette Abramowitz, MD, Psychiatry, Qi Zhi, DNP, Neurology)

Key Inclusion Criterias:

- Has a ≥ 4 week history of AjD as defined by DSM-5-TR with either depressed mood, or mixed anxiety and depressed mood confirmed by clinical interview
- AjD was instigated by either ALS, MS or Parkinson's disease

More information [NIH Info](#) or call Dedicated Neuromuscular Research Hotline (808) 564-6141 [Trial Info](#).



[Natalia Gonzalez, MD](#), Director of [Hawaii ALS and Neuromuscular Center](#), [Hawaii MS & Neuroimmunology Ctr.](#), Principal investigator is dual fellowship trained in Neuromuscular and Neuroimmunology, Clinical Assistant Professor of Medicine (Neurology), University of Hawai'i John Burns School of Medicine.



CLINICAL TRIALS